The Cancer Development and Progression (CDP) Program is one of three interactive research Programs of the Cancer Therapy and Research Center (CTRC) at the University of Texas Health Science Center at San Antonio (UTHSCSA). The primary focus of the CDP Program is laboratory-based studies of fundamental problems in cancer etiology, but always with an eye towards translational potential. The major thematic areas in the CDP Program are (1) Genomic Integrity and Aging and (2) Hormones and Chronic Inflammation. The overarching scientific objectives of the CDP Program are to: (1) integrate basic and translational research in genomic integrity, age-related cancer susceptibility, hormone actions, and chronic inflammation to obtain a deeper and broader picture of cancer development and progression;(2) foster transdisciplinary, synergistic, and highly complementary collaboration between basic and translational research within the CDP Program and in the EDT and CPPS Programs;and (3) translate laboratory findings into novel approaches in cancer prevention and treatment. The CDP program is comprised of 31 members. Twenty-eight members represent eight departments within the School of Medicine at the UTHSCSA. Two members are from the University of Texas at Austin. The CDP Program members have $7,290,029 of peer-reviewed cancer-related funding (33 grants). Of those, $2,195,289 are from 10 NCI grants. Over the last funding period the CDP Program has 271 peer-reviewed cancer-related publications of which 26% are intra-programmatic collaborafions and 22% are inter-programmatic collaborations.
The Cancer Development and Progression (CDR) Program members perform cutting-edge laboratory-based cancer research to understand fundamental problems in cancer etiology with a continual focus on translational potential.
|Ghosh, Sagar; Hughes, Daniel; Parma, Dorothy Long et al. (2014) Association of obesity and circulating adipose stromal cells among breast cancer survivors. Mol Biol Rep 41:2907-16|
|Meng, Jia; Lu, Zhiliang; Liu, Hui et al. (2014) A protocol for RNA methylation differential analysis with MeRIP-Seq data and exomePeak R/Bioconductor package. Methods 69:274-81|
|Gong, Jingjing; Muñoz, Amanda R; Chan, Daniel et al. (2014) STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth. Oncotarget 5:2529-41|
|Fok, Wilson C; Livi, Carolina; Bokov, Alex et al. (2014) Short-term rapamycin treatment in mice has few effects on the transcriptome of white adipose tissue compared to dietary restriction. Mech Ageing Dev 140:23-9|
|Morales, Liza D; Casillas Pavón, Edgar A; Shin, Jun Wan et al. (2014) Protein tyrosine phosphatases PTP-1B, SHP-2, and PTEN facilitate Rb/E2F-associated apoptotic signaling. PLoS One 9:e97104|
|Mousavi, Seyed Mohsen; Sundquist, Jan; Hemminki, Kari (2014) Risk of Kaposi sarcoma among immigrants to Sweden. Acta Derm Venereol 94:476-7|
|Ankerst, Donna P; Boeck, Andreas; Freedland, Stephen J et al. (2014) Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol 32:185-91|
|Biswas, Tanuka; Gu, Xiang; Yang, Junhua et al. (2014) Attenuation of TGF-* signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model. Cancer Lett 346:129-38|
|Ramirez, Amelie G; Munoz, Edgar; Holden, Alan E C et al. (2014) Incidence of hepatocellular carcinoma in Texas Latinos, 1995-2010: an update. PLoS One 9:e99365|
|Bansal, H; Yihua, Q; Iyer, S P et al. (2014) WTAP is a novel oncogenic protein in acute myeloid leukemia. Leukemia 28:1171-4|
Showing the most recent 10 out of 616 publications